COST-EFFECTIVENESS OF ASENAPINE VS. ATYPICAL ANTIPSYCHOTICS USED IN TURKEY IN THE TREATMENT OF BIPOLAR I DISORDER

Author(s)

Pala M1;Özdemir S*1, Ozdemir O2 1Lundbeck, Istanbul, Turkey, 2Yorum Consultancy Ltd., Istanbul, Turkey

OBJECTIVES: Asenapine is a new atypical antipsychotic approved in Turkey for the treatment of bipolar I disorder (BD-I) and schizophrenia. Asenapine has demonstrated comparable antimanic efficacy over olanzapine in a head-to-head study. However, unlike olanzapine, asenapine is associated with a favorable metabolic profile as well as with a minimal weight gain. Post-hoc analyses of a clinical study vs. olanzapine illustrated higher incidence of developing metabolic syndrome (MetS) with olanzapine than with asenapine after 52 weeks of treatment. The aim of this study is to assess the cost-effectiveness of asenapine in the treatment of BD-I compared with the most widely used atypical antipsychotics with a focus on the long-term consequences of MetS which increases the risk of diabetes and cardiovascular diseases (CVD).  METHODS: Perspective of National Pharmaceutical Reimbursement Authority was applied and life expectancy horizon was adopted. Risks of metabolic syndrome after 52 weeks of treatment were derived from randomized clinical studies of asenapine and indirect comparison of other atypical antipsychotics vs olanzapine. Risks of developing diabetes and CVD were based on published risk models. Treatment costs associated with metabolic consequences as well as cost of atypical antipsychotics were derived from local sources. Number of diabetes and CVD avoided is used as effectiveness measure in the model. RESULTS: Asenapine dominates (more effective and less expensive) all atypical antipsychotics in the treatment of BD-I. Compared to olanzapine, quetiapine, aripiprazole, risperidone and paliperidone (all genericized), asenapine was associated with incremental total costs of 2418 TL, 1786 TL, 804 TL and 877 TL; and associated with incremental total number of diabetes & CVD avoided of 0.054, 0.038, 0.010 and 0.037 respectively.  CONCLUSIONS: The lower incidence of developing MetS associated with asenapine compared to olanzapine and other atypicals is associated with lower treatment costs and lower incidence of diabetes and CVD in Turkey.

Conference/Value in Health Info

2013-11, ISPOR Europe 2013, The Convention Centre Dublin

Value in Health, Vol. 16, No. 7 (November 2013)

Code

PMH41

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Mental Health

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×